Arcus Biosciences Forecast, price target & analysts
Arcus Biosciences Target price 2025 - Analyst rating & recommendation
Arcus Biosciences Classifications & Recommendation:
Arcus Biosciences Price Target
| Target Price | $32.55 |
| Price | $7.85 |
| Potential |
314.59%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Arcus Biosciences 2026 .
The average Arcus Biosciences target price is $32.55.
This is
314.59%
register free of charge
$46.00
485.99%
register free of charge
$17.00
116.56%
register free of charge
|
|
| A rating was issued by 13 analysts: 11 Analysts recommend Arcus Biosciences to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Arcus Biosciences stock has an average upside potential 2026 of
314.59%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 258.00 | 154.46 |
| 120.51% | 40.13% | |
| EBITDA Margin | -116.28% | -274.69% |
| 58.01% | 136.23% | |
| Net Margin | -112.21% | -246.81% |
| 65.69% | 119.95% |
10 Analysts have issued a sales forecast Arcus Biosciences 2025 . The average Arcus Biosciences sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Arcus Biosciences EBITDA forecast 2025. The average Arcus Biosciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Arcus Biosciences Analysts have issued a net profit forecast 2025. The average Arcus Biosciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.14 | -4.13 |
| 24.34% | 31.53% | |
| P/E | negative | |
| EV/Sales | 0.30 |
11 Analysts have issued a Arcus Biosciences forecast for earnings per share. The average Arcus Biosciences EPS is
This results in the following potential growth metrics and future valuations:
Arcus Biosciences...
Current Arcus Biosciences Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Feb 19 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 06 2024 |
| Barclays |
Locked
➜
Locked
|
Locked | Oct 25 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 24 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 26 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Feb 19 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 18 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Feb 18 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 06 2024 |
|
Locked
Barclays:
Locked
➜
Locked
|
Oct 25 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 24 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
